One of the oldest assumptions in aging biology has been that certain molecular damage accumulates irreversibly over a lifetime — that the chemical scars left by decades of metabolic activity simply cannot be undone. A new finding from Nature Communications directly challenges that assumption, demonstrating for the first time that a specific, stable aging modification can be enzymatically erased, even in human tissue samples from elderly donors.
The target is Nε-carboxymethyl-lysine (CML), one of the most prevalent advanced glycation end products (AGEs) found in long-lived proteins such as collagen, elastin, and lens crystallins. CML forms when proteins react with reducing sugars or oxidized lipids, and once formed, it had been classified as a terminal, irreversible adduct. Beyond structural damage, CML activates RAGE — the receptor for advanced glycation end products — triggering cascades of chronic inflammation and oxidative stress linked to metabolic disease, vascular aging, and neurodegeneration. The researchers developed CMLase, an enzyme created through directed evolution across a library exceeding 500 million variants. CMLase specifically oxidizes the CML adduct, chemically restoring the original lysine residue. Critically, efficacy was demonstrated not only in purified model proteins but also ex vivo in human tissue from elderly donors.
This work sits at a frontier where biochemistry meets longevity intervention. AGE accumulation is well-established as a biomarker and putative driver of tissue aging, yet until now the pharmacological strategy has been limited to preventing new AGE formation rather than reversing existing damage. CMLase represents a proof-of-concept for an entirely new repair paradigm. Key limitations remain: all data are in vitro and ex vivo, with no in vivo efficacy, pharmacokinetics, or safety data yet reported. Delivery of a therapeutic enzyme to collagen-rich tissues represents a substantial bioengineering challenge. Nevertheless, this finding is genuinely paradigm-shifting in framing irreversible molecular aging damage as a tractable enzymatic target.
